Macrophagic myofasciitis: an emerging entity

Gherardi, Romain K.; Coquet, M; Chérin, P.; Authier, François‐Jérôme; Laforêt, Pascal; Bélec, Laurent; Figarella‐Branger, Dominique; Mussini, Jean‐Marie; Pellissier, Jean‐François; Fardeau, Michel

doi:10.1016/s0140-6736(98)02326-5

Cited by 218 publications

(101 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients had normal results on both renal function tests and aluminum plasma levels, which lead the investigators to consider the likelihood of a focal accumulation of aluminum unrelated to passive deposition from the blood. Macrophage infiltrates were not observed elsewhere than in muscle in adult patients (Gherardi et al, 1998), and in fact the MMF lesion was detected completely in the deltoid muscle (Gherardi et al, 2001). Because aluminium salts are used as an adjuvant in several vaccines administered intramuscularly into deltoid and quadriceps muscles, it has been postulated that MMF may represent a rare and unusual reaction to intramuscular injections of aluminium-containing vaccines (Gherardi and Authier, 2003).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Mechanism of Action of Licensed Vaccine Adjuvants

Rambe

Giudice

Rossi³

et al. 2015

Int Curr Pharm J

View full text Add to dashboard Cite

Vaccines are some of the most effective tools for the prevention of infectious diseases. Adjuvants are included in vaccines for a variety of reasons: to increase the breadth of response, to lower antigen dose, to overcome limited immune response in some populations, or to enable complex combination vaccines. This study aims to review the safety of licensed vaccine adjuvants and describe their mechanism of action. Potential publications for inclusion were identified through a direct search of PubMed/Medline database. Results of online literature searches were supplemented by relevant papers cited in published studies along with the authors knowledge of published studies. To date, there are 5 licensed vaccine adjuvants in US and Europe: Aluminum salts (EU, US), MF59 (EU), AS03 (EU), AS04 (EU, US), and virosomes (EU). AS03 is not available as an adjuvant in other vaccines but included within the US governments National Stockpile. All vaccines that contain these adjuvants have been proven safe in clinical trials and post-marketing studies, with the exception of the AS03, for which the rare events of narcolepsy have been reported in some countries. Every adjuvant has a complex and often multifactorial immunological mechanism, usually poorly understood in vivo. The safety profile of an adjuvant, including the actual and hypothetical risks, is a critical component that can speed up or impede adjuvant development. The increasing understanding in adjuvant sciences is fundamental to the further development of new adjuvants.Rambe et al., International Current Pharmaceutical Journal, July 2015, 4(8): 420-431

show abstract

Section: Resultsmentioning

confidence: 99%

“…Twelve patients reported myalgia, nine reported arthralgia, six reported muscle weakness, five reported pronounced asthenia, and four reported fever. Abnormal laboratory findings were infrequently observed which included increased creatine kinase, increased erythrocyte sedimentation rate and myopathic electromyography (Gherardi et al, 1998).…”

Section: Safetymentioning

confidence: 99%

Safety and Mechanism of Action of Licensed Vaccine Adjuvants

Rambe

Giudice

Rossi³

et al. 2015

Int Curr Pharm J

View full text Add to dashboard Cite

show abstract

“…A double-blind cohort study completed about 10 years ago by a New Orleans group 6 presented a surprising outcome with respect to GWS. This study compared dosages of anti-squalene antibody serum in 114 Gulf War veterans and non-combat military employees (some healthy and some ill) with a control group comprised of 48 blood donors, 40 asymptomatic patients with systematic lupus erythematosis, 34 patients with silicone breast implants and 30 patients with chronic fatigue syndrome.…”

Section: Gws Was First Described In 1998mentioning

confidence: 99%